Search

Your search for "POAI" returned the following results.
Filter Results:
InvestorNewsBreaks

InvestorNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Names Seasoned Veteran as New Chief Business Officer

February 3, 2023

Predictive Oncology (NASDAQ: POAI) has announced a new chief business officer. Effective immediately, Pamela Bush, PhD, MBA, will take on the role as chief business officer and will oversee all business development including the partnering and growth strategies for the company. Specifically, the company observed that she will manage the company’s strategic, operational and financial […]

InvestorNewsBreaks

InvestorNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Names Computational Biology Pioneer as New Scientific Advisory Board Member

January 12, 2023

Predictive Oncology (NASDAQ: POAI) has announced a new member of its Scientific Advisory Board: Robert F. Murphy, PhD, a pioneer in the field of machine learning and analytics for biological data, will be joining the board and working with other experts in a variety of fields to guide the POAI’s scientific initiatives and growth strategy. […]

InvestorNewsBreaks

InvestorNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Expands Scientific Advisory Board to Appoint Genomics Expert

December 13, 2022

Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, today announced the appointment of Marc Malandro, Ph.D., to the company’s scientific advisory board. Dr. Malandro, a highly regarded scientific leader and expert in genomics, molecular biology, biochemistry and bioengineering, will serve alongside other key thought […]

InvestorNewsBreaks

InvestorNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Announces New Board Member

December 5, 2022

Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, has appointed a new board member; Matthew J. Hawryluk, PhD, will “help support the company’s strategic initiatives and commercialization efforts.” A well-known business executive in the pharma and biotech industries, Hawryluk currently serves as executive vice […]

InvestorNewsBreaks

InvestorNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Releases Q3 Financial Report, Corporate Update

November 11, 2022

Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, is reporting corporate updates and financial results for its Q3 quarter, ended Sept. 30, 2022. According to the announcement, the report reflects revenue growth and increased gross profit margin as compared to prior year periods. Highlights […]

InvestorNewsBreaks

InvestorNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Appoints Key Life Sciences Thought Leader to Its Board

October 25, 2022

Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, today announced its appointment of David S. Smith, JD, to the company’s board of directors. Smith is a life sciences and corporate attorney, veteran biotech industry executive and leading authority on the legal issues surrounding the […]

InvestorNewsBreaks

InvestorNewsBreaks – Predictive Oncology (NASDAQ: POAI) Names Seasoned Senior Exec, Biotech Entrepreneur as New CEO

October 20, 2022

Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, has appointed Raymond F. Vennare as its new chief executive officer, effective Nov. 1, 2022; Vennare will also assume the role of board chair. Vennare has more than 30 years’ experience building and leading biotechnology and […]

InvestorNewsBreaks

InvestorNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Releases Q2 Financial Report

August 12, 2022

Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, is reporting its numbers for second quarter 2022, or the period ended June 30, 2022. According to the announcement, the report indicates a strong balance sheet with a solid cash balance, commensurate equity and no debt. […]

InvestorNewsBreaks

InvestorNewsBreaks – Predictive Oncology (NASDAQ: POAI) Names Chief Scientific Officer, Shares R&D Update

July 26, 2022

Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, has appointed Julia Kirshner, PhD, as its new chief scientific officer. Kirshner has been serving as POAI’s senior vice president as well as president of the company’s zPREDICTA division, a company that she originally founded in […]

InvestorNewsBreaks

InvestorNewsBreaks – Predictive Oncology (NASDAQ: POAI) Closes on $7.2M in Registered Direct Offerings

May 19, 2022

Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, announced that it has closed on two direct offerings. The offerings, which were available concurrently, were with different institutional investors and results in approximately $7.2 million in gross proceeds for the company, before the deduction of […]

InvestorNewsBreaks

InvestorNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Announces $7.2M Registered Direct Offerings

May 16, 2022

Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, today announced its entry into definitive agreements with several institutional investors for the issuance and sale of shares of its common stock, with related agreements regarding certain stock purchase warrants, in connection with two concurrent offerings. […]

InvestorNewsBreaks

InvestorNewsBreaks – Predictive Oncology (NASDAQ: POAI) Releases Q1 Financial Report, Corporate Update

May 13, 2022

Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, has released financial results from its first quarter, the period ending March 31, 2022. Highlights from the report include recognized revenue of $314,568 for the quarter, up from $280,317 reported for the same period in 2021; […]

InvestorNewsBreaks

InvestorNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Appoints Experienced Leader as Senior Director of Marketing

April 26, 2022

Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to develop optimal cancer therapies, today announced that Theresa Ferguson has been named senior director of marketing. As the company’s senior marketing leader, Ferguson steps in as Predictive Oncology begins commercialization of its knowledge-driven technologies, applying artificial intelligence (“AI”) to develop personalized […]

InvestorNewsBreaks

InvestorNewsBreaks – Predictive Oncology (NASDAQ: POAI) Releases Year-End 2021 Financial Report, Corporate Update

April 1, 2022

Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, is reporting its financial and corporate results for the year ended Dec. 31, 2021. Highlights of the report include positive results of POAI subsidiary Helomics’ Discovery 21 proof of concept of its PeDAL(R) platform, added revenue […]

InvestorNewsBreaks

InvestorNewsBreaks – Predictive Oncology (NASDAQ: POAI) Calls Validation of Discovery 21 Proof-of-Concept Campaign a ‘Key Milestone’

March 24, 2022

Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, announced that it had reached a key milestone toward monetizing its unique approach to leverage AI in oncology drug discovery. The company noted that earlier this year its proprietary Discovery 21 proof-of-concept campaign showed the ability […]

InvestorNewsBreaks

InvestorNewsBreaks – Predictive Oncology (NASDAQ: POAI) Announces Plans to Market Proprietary AI Drug-Discovery Platform

January 27, 2022

Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, is focused on establishing a position as a first mover in the artificial intelligence (“AI”)-powered, drug-discovery market. According to the announcement, the company anticipates the space will reach $20 billion in the next three years. As […]

InvestorNewsBreaks

InvestorNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Announces Strong Results from Discovery 2021 Program

January 13, 2022

Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to develop personalized cancer therapies, today reported the preliminary results of its Discovery 2021 program. According to the update, Predictive Oncology’s Helomics subsidiary’s evaluation demonstrated its proprietary artificial intelligence (“AI”) program CoRE(TM) (Computational Research Engine), combined with its tumor profile data and […]

InvestorNewsBreaks

InvestorNewsBreaks – Predictive Oncology (NASDAQ: POAI) Reschedules Adjournment of Annual Stockholder Meeting

December 28, 2021

Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, announced a new time for its annual meeting of stockholders. The meeting was originally scheduled for Dec. 23, 2021, at 3 p.m. CT, but upon convening was immediately adjourned because a required quorum was not in […]

InvestorNewsBreaks

InvestorNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Issues Year-End Shareholder Update

December 21, 2021

Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to develop personalized cancer therapies, today issued a year-end corporate update. Among the highlights, the update discussed POAI’s November 2021 acquisition of zPREDICTA, a cutting-edge cancer based company with a proven commercial and scientific record and patented 3D cell culture platform. “zPREDICTA’s […]

InvestorNewsBreaks

InvestorNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Welcomes New SVP of Strategic Sales and Business Development

December 7, 2021

Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to develop personalized cancer therapies, today announced that Pamela Bush, Ph.D., MBA will be joining the company’s leadership team as SVP of Strategic Sales and Business Development. According to the update, Bush brings to POAI’s leadership team nearly two decades of experience […]

InvestorNewsBreaks

InvestorNewsBreaks – Predictive Oncology (NASDAQ: POAI) Announces zPREDICTA Acquisition

December 1, 2021

Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to develop personalized cancer therapies, has completed the acquisition of zPREDICTA. According to the announcement, the acquisition provides an immediate new anticipated revenue stream for POAI as well as supporting the company focus on developing new cancer therapies from drug discovery through […]

InvestorNewsBreaks

InvestorNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Launches Website Showcasing AI-Driven Advancements in Cancer Research

October 19, 2021

Predictive Oncology (NASDAQ: POAI), an oncology and cancer research company using big data and machine learning to improve pharmaceutical development and predictive treatment outcomes, today announced the launch of a website that emphasizes its role in advancing its mission. According to the update, the website features information about Predictive Oncology and its subsidiaries, which are […]

InvestorNewsBreaks

InvestorNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Announces Approval of Charter Amendment

August 18, 2021

Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, today announced that on Aug. 17, 2021, the stockholders approved an amendment to the company’s certificate of incorporation. The amendment, effective Aug. 17, 2021, increased the number of authorized shares of company common stock from 100,000,000 […]

News Articles

Predictive Oncology Inc. (NASDAQ: POAI) Subsidiary AI Model Predicts Cancer Outcomes, Leads to New Therapies

August 17, 2021

AI models of genomic data can predict cancer outcomes, which can then help personalize ovarian cancer treatments Results come from Helomics’ work on the 100,000 Genomes Project in Genomics England’s National Genomic Research Library Model learns patterns in genetic mutations of patients’ tumors, uses that knowledge to predict patient survival In an historic announcement in […]

InvestorNewsBreaks

InvestorNewsBreaks – Predictive Oncology (NASDAQ: POAI) Announces Adjournment of Special Meeting of Stockholders

August 11, 2021

Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, has adjourned its Special Meeting of Stockholders. The meeting was convened on Aug. 10, 2021, at 3 p.m. CT, and then adjourned, with a plan to reconvene on Aug. 17, 2021, at 3 p.m. CT. The […]

InvestorNewsBreaks

InvestorNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Eyes Expanded Customer Base, Multiple Collaborations, Fulfillment of Researchers’ Needs

July 27, 2021

Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, recently announced that two of its four subsidiaries, Soluble Biotech and TumorGenesis, are expanding their services with the construction of new good manufacturing practices (“GMP”) laboratories. For Soluble Biotech, the GMP facility ramps up its formulation […]

InvestorNewsBreaks

InvestorNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Stands Distinct in Precision Medicine

July 16, 2021

Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, is leveraging its unique, historical database of the drug responses of over 150,000 patient tumors to build data-driven predictive models of tumor drug response. These models will provide actionable insights critical to both new drug development […]

InvestorNewsBreaks

InvestorNewsBreaks – Predictive Oncology Inc.’s (NASDAQ: POAI) Subsidiaries Showcase Products, Services at BIO Digital

July 9, 2021

Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, participated in the second leg of the Biotechnology Innovation Organization (“BIO”) Digital, a premier international biotech partnering event held virtually on June 10-11 and 14-18, 2021, through its three subsidiaries. “While informative, the thrust of attending […]

News Articles

Predictive Oncology Inc. (NASDAQ: POAI) Companies Build New Labs, Expand Services for New Drug Discoveries

July 7, 2021

Two of Predictive Oncology’s four subsidiaries are constructing new Good Manufacturing Practices laboratories to offer additional services to customers With its new GMP lab, Soluble Biotech will provide customers formulations that can go directly to clinical trials, as well as manufacture proprietary media used in its chromatography kits TumorGenesis will use its GMP lab to […]

News Articles

Predictive Oncology Inc. (NASDAQ: POAI) Stands Strong as Innovator, Leader in Precision Medicine

July 2, 2021

Company plans to use proceeds from direct offering for business development, drug repurposing and discovery and expansion of its laboratory facilities POAI portfolio spans four different subsidiaries, including list of assets rivaling best operators in the space Predictive Oncology is strong standout in precision medicine Predictive Oncology (NASDAQ: POAI) has closed on its registered direct […]

InvestorNewsBreaks

InvestorNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Bringing Researchers Next-Level Tools for Hard-to-Treat Diseases

Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, is looking to give oncology drug developers an upper hand, thereby increasing the chances of the drugs’ success from the onset. “Raising the success rate for experimental cancer drugs starts in the laboratory, where leading-edge technology […]

News Articles

Three Predictive Oncology Inc. (NASDAQ: POAI) Companies Participate in Popular Biotechnology Innovation Organization Digital Conference

June 24, 2021

More than 3,200 pharmaceutical and biotech companies, plus government and academic organizations attended latest BIO Conference Predictive Oncology’s Helomics, TumorGenesis, Soluble Biotech all attended the virtual conference from June 14-18, 2021 Companies leveraged different components of the conference to entertain new partnerships or customers Every industry has a revolving calendar of events, but some are […]

News Articles

Predictive Oncology Inc.’s (NASDAQ: POAI) TumorGenesis Partners with Cellevate for New Approach to Ovarian Cancer

June 22, 2021

Collaboration will use TumorGenesis’ expertise in cancer cell culture growth media in combination with Cellevate’s specialty in emerging field of nanofiber matrixes.  Cutting-edge technology can help avoid mistakes in $2.6 billion process of bringing new drugs through FDA process. Coupling companies’ technology will give researchers ability to grow ovarian cancer tissues in 3D matrix support […]

InvestorNewsBreaks

InvestorNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Building Strong Commercial Pipeline for Unique PeDAL(TM) Platform

June 2, 2021

Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, continues to create value for a growing customer base through its subsidiaries. Researchers from one such subsidiary, Helomics, recently completed key sequencing milestones for ovarian cancer to help build its AI-driven models of the disease. “We […]

News Articles

Predictive Oncology Inc. (NASDAQ: POAI) Subsidiary Highlights, Q1 Financials Herald Bright Horizon for Company

May 28, 2021

POAI announced that total stockholders’ equity increased by nearly $33 million to $35.5 million Financial report notes net proceeds of $35.6 million from private placement, direct offering, warrant exercises Company subsidiaries reached several milestone achievements throughout the quarter. Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and […]

InvestorNewsBreaks

InvestorNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Adds Insight, Strengthens Positioning Through Strategic Board Appointment

May 26, 2021

Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, recently expanded its board of directors with the appointment of Dr. Christina Jenkins. Dr. Jenkins holds capital markets expertise coupled with health care experience through roles that span clinical medicine, venture capital, health plans, and health […]

InvestorNewsBreaks

InvestorNewsBreaks – Predictive Oncology Inc.’s (NASDAQ: POAI) Helomics CTO Discusses Revolutionizing Drug Discovery in Bell2Bell Podcast

May 18, 2021

Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, was featured in a recent episode of The Bell2Bell Podcast. Predictive Oncology’s newly appointed CEO Mel Engle, CFO Bob Myers and Mark Collins, chief technical officer of the company’s Helomics subsidiary, joined the program to share […]

News Articles

Predictive Oncology Inc. (NASDAQ: POAI) Appoints Venture Investor Dr. Christina Jenkins to Board of Directors

POAI appoints strategic advisor, venture investor Dr. Christina Jenkins to board of directors Dr. Jenkins’ experience spans work in capital markets, clinical medicine, public healthcare systems  Other roles include current Board Director for Independence Health Group, Venture Partner at Phoenix Venture Partners, Board Observer for Madorra Inc., board advisory roles at multiple value-generating healthcare companies  […]

News Articles

Predictive Oncology’s (NASDAQ: POAI) C-Level Leaders Provide Company, Operations Update on New Podcast

May 11, 2021

Bell2Bell podcast features company CEO, CFO, CTO of Helomics subsidiary POAI is “in probably the best situation we’ve been in since the existence of the company,” reports CFO Company anticipates revenue from its unique PeDAL platform Three Predictive Oncology (NASDAQ: POAI) executives were featured guests on a recent Bell2Bell podcast (https://ibn.fm/DumLs). Newly appointed CEO Mel […]

InvestorNewsBreaks

InvestorNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Advancing Solutions for ‘Personalized Medicine at Its Finest’

May 6, 2021

Predictive Oncology (NASDAQ: POAI) has made several advances in providing cancer treatment solutions. Its subsidiary, TumorGenesis, “specializes in technology that preserves a patient’s unique cancer tissue biological signatures, thereby allowing researchers to study cancer in the laboratory using samples that reflect actual tumors found in a patient,” reads a recent article.  TumorGenesis’ transformational technology enables […]

No ResultsNo content matches your search/filter.

 

 

 

Get Started with InvestorWire

To distribute a release in the next 24 hours. Contact our client services team.

(310) 299-1717

Distribute a press release. Submit your release to get started.

Submit Press Release

Set up a Live demonstration. Schedule a date and time that works for you.

Schedule a LIVE Demo

Press Distribution

Explore Press Distribution Solutions

All releases include an unlimited word count* with full wire-grade syndication, our press release enhancement service, and a follow-up InvestorNewsBreak article distributed to thousands of editorial syndication partners.

Discover Add-on Solutions

Increase the impact of your achievements by adding these exclusive solutions from InvestorWire, delivered in conjunction with the InvestorBrandNetwork (IBN).